# Multiple Antigen-Engineered DC Vaccine for Melanoma

> **NCT01622933** · PHASE1 · COMPLETED · sponsor: **Lisa H. Butterfield, Ph.D.** · enrollment: 35 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** DC Vaccine + IFN
- **BIOLOGICAL:** AdVTMM2/DC Vaccination

## Key facts

- **NCT ID:** NCT01622933
- **Lead sponsor:** Lisa H. Butterfield, Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2016-05
- **Final completion:** 2017-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01622933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01622933, "Multiple Antigen-Engineered DC Vaccine for Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01622933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*